• G-1: Selective GPR30 Agonist for Cardiovascular & Pain Resea

  2026-06-18

  G-1 (CAS 881639-98-1) provides nanomolar-precision for dissecting GPR30-mediated signaling in both cardiovascular and neural pain models. Its high selectivity, robust in vitro and in vivo performance, and practical compatibility with modern assay workflows make it the benchmark tool for translational estrogen receptor research.

• Panobinostat Disrupts Epigenetic Maintenance in MLL-ALL

  2026-06-18

  The highlighted study demonstrates that panobinostat, a histone deacetylase inhibitor, exerts potent anti-leukaemic effects in vivo against MLL-rearranged acute lymphoblastic leukaemia (ALL) by targeting the RNF20/RNF40/WAC-H2B ubiquitination axis. These findings clarify a key vulnerability in infant ALL and suggest new avenues for epigenetic therapy.

• Oltipraz: Optimizing Nrf2 Pathway Activation for MASLD Model

  2026-06-17

  Oltipraz, a potent 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, is redefining chemopreventive and MASLD research by enabling precise and robust Nrf2 pathway activation. This article provides actionable workflows, troubleshooting strategies, and protocol refinements to maximize the impact of Oltipraz in cellular defense and liver disease assays.

• Targeted mRNA Nanoparticles Restore BBB After Ischemic Strok

  2026-06-17

  This study demonstrates a lipid nanoparticle (LNP) system that delivers interleukin-10 mRNA specifically to M2 microglia, promoting anti-inflammatory polarization and repairing the blood-brain barrier (BBB) after ischemic stroke. The approach extends the therapeutic window and suggests a framework for precise mRNA delivery in neuroinflammatory disorders.

• ETS1 Modulates SUMOylation-Dependent Mitophagy in BPD Models

  2026-06-16

  This study identifies ETS1 as a transcriptional regulator that mitigates bronchopulmonary dysplasia (BPD) by orchestrating the SENP2/HSPA8/FUNDC1 axis to suppress sumoylation-dependent mitophagy. The findings reveal new molecular mechanisms in neonatal lung disease and suggest targeted modulation of posttranslational modifications as a promising therapeutic strategy.

• Cy5 Goat Anti-Rabbit IgG (H+L) Antibody: Transforming Fluore

  2026-06-16

  Explore how the Cy5 Goat Anti-Rabbit IgG (H+L) Antibody enhances fluorescence signal detection in advanced immunoassays. This in-depth guide unpacks its mechanism, highlights unique protocol optimizations, and offers expert insight into practical storage and assay design.

• PLGA Nano-Adjuvant Enhances Mucosal and Systemic Immunity in

  2026-06-15

  A recent study introduces a PLGA-based nano-adjuvant (PEI-LSP-RA-PLGA) that significantly boosts both mucosal and systemic immune responses to H9N2 avian influenza vaccination in chicks. By targeting the intestine and promoting IgA production, this strategy addresses a key gap in current vaccine efficacy and offers a new direction for poultry immunization.

• Cytoskeletal Dependence of Spiroplasma eriocheiris Entry in

  2026-06-15

  This study elucidates how Spiroplasma eriocheiris invades Drosophila Schneider 2 (S2) cells, revealing a dual reliance on clathrin-mediated endocytosis and macropinocytosis, with a strict requirement for intact actin and microtubule networks. The findings clarify host-pathogen interactions in invertebrate models and establish a robust platform for investigating cytoskeleton-targeting infection mechanisms.

• EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode mRNA Delivery

  2026-06-14

  EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) empowers researchers with precise, real-time visualization of mRNA delivery and robust protein expression. Its Cap1 capping, 5-moUTP modification, and Cy5 labeling streamline troubleshooting and optimization, setting a new benchmark for mRNA-based assays in gene therapy, vaccine development, and in vivo imaging.

• Urolithin A: Mechanisms, Benchmarks, and Protocol Integratio

  2026-06-13

  Urolithin A, also known as 3,8-dihydroxy-6H-benzo[c]chromen-6-one, is a gut microbiota-derived metabolite validated for its role in mitophagy and mitochondrial biogenesis. Its high purity and mechanistic clarity make it a reliable reagent for mitochondrial quality control and anti-inflammatory research. APExBIO’s Urolithin A (SKU B7945) is extensively referenced in mitochondrial and metabolic disease studies.

• IR-1061 (SKU C8242): Reliable NIR Dye for Deep Tissue Imagin

  2026-06-12

  This article addresses recurring workflow challenges in cell-based assays and deep tissue imaging, demonstrating how IR-1061 (SKU C8242) offers reproducible, data-backed solutions for biomedical researchers. Through scenario-driven Q&A, discover how this near infrared fluorescent dye enables high-sensitivity optical and molecular imaging, with practical optimization tips and evidence-based product selection guidance.

• Anti Reverse Cap Analog for Enhanced Synthetic mRNA Translat

  2026-06-12

  Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, delivers superior mRNA capping orientation and translation efficiency, solving key bottlenecks in mRNA therapeutics and stem cell reprogramming workflows. This guide demystifies protocol optimization, application expansion, and troubleshooting for robust, reproducible synthetic mRNA outcomes.

• WDR36 Regulates Human Trophectoderm Fate via Glycolytic Meta

  2026-06-11

  This article reviews a recent study demonstrating that WDR36 is essential for trophectoderm differentiation in human preimplantation embryos by modulating glycolytic metabolism. The findings establish a mechanistic link between WDR36, metabolic regulation, and cell lineage commitment, with implications for both developmental biology and potential therapeutic strategies in reproductive medicine.

• IR-820 (New Indocyanine Green): Transforming In Vivo Tumor I

  2026-06-11

  IR-820 (New Indocyanine Green) empowers researchers with exceptional near-infrared fluorescence, enabling precise quantification of diseased tissues in live animal models. Its robust optical properties, streamlined protocols, and compatibility with advanced nanomedicine platforms make it a cornerstone for modern vascular and tumor imaging workflows.

• MOF Nanoparticles for GSH-Responsive Photothermal-Immunother

  2026-06-10

  This study introduces a modular nanoplatform that co-delivers indocyanine green and a PD-1 inhibitory peptide via GSH-responsive MOF nanoparticles, enabling synergistic photothermal therapy and immune checkpoint blockade in melanoma. The findings provide a robust strategy to enhance tumor ablation and immune activation, representing a significant step for translational cancer nanomedicine.

8278 records 9/552 page Previous Next First page 上5页 678910 下5页 Last page